Get the latest news, insights, and market updates on APGE (Apogee Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best 52-week high stocks to buy right now. On December 3, TD Cowen’s Tyler Van Buren reiterated a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE). Earlier, on November 13, Canaccord Genuity’s Edward Nash reiterated a Buy rating on Apogee Therapeutics with a $89 price target, citing its […] Dec 9, 2025 - $APGE
Assessing Apogee Therapeutics (APGE) Valuation After Recent Surge in Investor Interest
Apogee Therapeutics (APGE) shares have surged nearly 20% over the past week, sparking investor curiosity about what is fueling this momentum. The stock has also delivered strong returns over the past month and quarter. See our latest analysis for Apogee Therapeutics. Apogee Therapeutics has been catching attention thanks to its rapid run-up lately. The stock's 90-day share price return of nearly 76% stands out, and its year-to-date and one-year total shareholder returns both hover just below... Nov 16, 2025 - $APGE
Why Apogee Therapeutics (APGE) Is Up 19.7% After Strong APG333 Trial Data and Cash Infusion
Apogee Therapeutics announced positive interim Phase 1 results for APG333, highlighting the potential for extended 3- and 6-month dosing intervals and favorable safety data in healthy volunteers, alongside an increased net loss of US$65.02 million for the third quarter ended September 30, 2025. The company’s strengthened financial position, bolstered by a US$345 million public offering, positions Apogee to fund ongoing and future clinical trials across its expanding pipeline. We’ll explore... Nov 15, 2025 - $APGE
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar TherapeuticsLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “ Nov 11, 2025 - $APGE
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing Results support development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333) for respiratory indications APG333 was well tolerated across all cohorts with doses of up to 1,000 mg SAN FRANCISCO and BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Apog Nov 10, 2025 - $APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026 Interim Phase 1 results of APG333 in healthy volunteers reported today exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppresse Nov 10, 2025 - $APGE
Apogee Therapeutics to Participate in Upcoming Conferences
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd Annual Healthcare Innovation Conference Date: Tuesday, November 11, 2025Fireside Chat Time: 1:30 p.m. ET Stifel 2025 Healthcare ConferenceDate: Wednesday, November 12, 2025Fireside Chat Time: 11:20 a.m. ET TD Cowen Immunology and Inflammation Virtual Summit Date: Thursday, November Nov 3, 2025 - $APGE
Why Apogee Therapeutics (APGE) Is Up 6.1% After $300 Million Raise to Advance APG777
Earlier this week, Apogee Therapeutics secured a US$300 million fundraising round to advance its lead drug candidate APG777 for atopic dermatitis, which is designed for less frequent dosing and showed strong efficacy in Phase 2 trials. This development has led to renewed analyst interest and increased investor confidence, especially as APG777 is positioned as a potential alternative to leading treatments like Dupixent. We'll examine how the combination of strong Phase 2 data and successful... Oct 31, 2025 - $APGE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple